Malchair, P.; Giol, J.; Jacob, J.; Villoria, J.; Carnaval, T.; Videla, S.
Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant. Pathogens 2025, 14, 533.
https://doi.org/10.3390/pathogens14060533
AMA Style
Malchair P, Giol J, Jacob J, Villoria J, Carnaval T, Videla S.
Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant. Pathogens. 2025; 14(6):533.
https://doi.org/10.3390/pathogens14060533
Chicago/Turabian Style
Malchair, Pierre, Jordi Giol, Javier Jacob, Jesús Villoria, Thiago Carnaval, and Sebastián Videla.
2025. "Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant" Pathogens 14, no. 6: 533.
https://doi.org/10.3390/pathogens14060533
APA Style
Malchair, P., Giol, J., Jacob, J., Villoria, J., Carnaval, T., & Videla, S.
(2025). Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant. Pathogens, 14(6), 533.
https://doi.org/10.3390/pathogens14060533